Cue Biopharma

NASDAQ CUE

Data sourced from

and

Download Data

Cue Biopharma Sales to Working Capital Ratio 3 year CAGR for the quarter ending March 31, 2024: 36.22%

Cue Biopharma Sales to Working Capital Ratio 3 year CAGR is 36.22% for the quarter ending March 31, 2024, a 176.87% change year over year. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Cue Biopharma Sales to Working Capital Ratio for the quarter ending March 31, 2023 was 0.00, a -78.04% change year over year.
Cue Biopharma Sales to Working Capital Ratio for the quarter ending March 31, 2022 was 0.02, a -39.36% change year over year.
Cue Biopharma Sales to Working Capital Ratio for the quarter ending March 31, 2021 was 0.03, a 11.02% change year over year.
Cue Biopharma Sales to Working Capital Ratio for the quarter ending March 31, 2020 was 0.02, a 33.10% change year over year.

NASDAQ: CUE

Cue Biopharma

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
IPO Date	Jan. 2, 2018
Location	United States
Headquarters	21 Erie Street, Cambridge, MA, United States, 02139
Employees	53
Sector	Healthcare
Industry	Biotechnology

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Key trends